Reading MBX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MBX free→Reading MBX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MBX free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it has a capital-unfriendly stance. Risk is elevated, and the sector backdrop is a headwind, which may impact future performance. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $38.98. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.89x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
15 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $-0.60. 6 raised, 0 cut, 8 covering analysts.
0 upgrades, 0 downgrades / 30d. 92% of analysts rate Buy.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$264.
How much price usually moves either way.
On a bad day, this stock has moved -$876.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,760.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The data will show if canvuparatide is effective. Positive results could boost confidence in the drug's potential.
Confirms:Data from the past year shows a responder rate over 63% in patients treated with canvuparatide.
Disproves:Less than 63% of patients treated with canvuparatide respond.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for MBX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. On June 12, 2026, the Company announced one-year data from the Phase 2 Avail™ and OLE clinical trials of canvuparatide in adult patients with chronic HP. The update is summarized below. Key Findings from the 12-Week Avail™ Phase 2 Trial and One-Year OLE Responder Rate • At 12 Weeks: As previously reported, 63% of canvuparatide-treated patients (30/48) achieved the primary composite endpoint compared with 31% of placebo-treated patients (5/16) (p=0.042). The primary endpoint was…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
MBX MBX Biosciences, Inc. | — | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Plan to advance once-weekly canvuparatide into a Phase 3 trial for chronic hypoparathyroidism in Q3 2026.
Stated in 2 of last 2 quarters. The company confirmed the regulatory path for canvuparatide and plans to advance it to a Phase 3 trial in Q3 2026. Financials show ongoing net losses, with net income at -$23.5M in 2026-Q1, indicating limited progress in financial improvement but a clear focus on advancing product development.
“Company plans to advance once-weekly canvuparatide into a Phase 3 trial in Q3 2026.”
“Confirmed regulatory path toward an NDA submission for canvuparatide.”
Expect to expand the obesity portfolio in 2026 with two additional obesity candidates.
Newly stated in 2026-Q1. The company plans to expand its obesity portfolio with two new candidates in 2026. Financials show a net income of -$23.5M in 2026-Q1, reflecting ongoing financial challenges. The expansion plan is a strategic move to diversify and potentially improve future revenue streams.
“Company expects to expand its obesity portfolio in 2026 with two additional candidates.”
Entered into a lease agreement for new office and laboratory space in Burlington, MA.
Newly stated in 2026-Q1. The company has entered into a lease agreement for new office and laboratory space, indicating a strategic investment in infrastructure. Despite this expansion, financials show a net income of -$23.5M in 2026-Q1, highlighting ongoing financial pressures.
“Entered into a lease agreement for 13,642 sq ft of new office and lab space in Burlington, MA.”
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 4, 2026, MBX Biosciences, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). As further described under
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto), is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto), is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer On February 25, 2026, the Company and Richard Bartram entered into a separation agreement pursuant to which Mr. Bartram will resign as Chief Financial Officer of the Company. He will continue his employment with the Company as its Chief Financial Officer through March 15, 2026. Mr. Bartram has agreed to serve as…